Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
Alternaturals, Inc. manufactures and sells alternative healthcare products includi...
Alternaturals, Inc. manufactures and sells alte...
With 40 million infertile people worldwide, MedAnswers connects patients with mult...
With 40 million infertile people worldwide, Med...
LeMaitre Vascular is a leading global innovator, manufacturer and marketer of devi...
LeMaitre Vascular is a leading global innovator...
Join the National Investor Network and get the latest information with your interests in mind.